स्विट्ज़रलैंड - जर्मन - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - daratumumabum - konzentrat zur herstellung einer infusionslösung - daratumumabum 400 mg, histidinum, histidini hydrochloridum monohydricum, sorbitolum 1093.0 mg, methioninum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 5 ml. - multiples myelom - biotechnologika

स्विट्ज़रलैंड - जर्मन - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - panitumumabum - konzentrat zur herstellung einer infusionslösung - panitumumabum 100 mg, natrii acetas trihydricus, natrii chloridum, acidum aceticum glaciale, aqua ad iniectabile q.s. ad solutionem pro 5 ml corresp. natrium 17.25 mg. - metastasierendes kolorektales karzinom - biotechnologika

स्विट्ज़रलैंड - जर्मन - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - panitumumabum - konzentrat zur herstellung einer infusionslösung - panitumumabum 400 mg, natrii acetas trihydricus, natrii chloridum, acidum aceticum glaciale, aqua ad iniectabile q.s. ad solutionem pro 20 ml corresp. natrium 69 mg. - metastasierendes kolorektales karzinom - biotechnologika

स्विट्ज़रलैंड - जर्मन - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ofatumumabum - konzentrat zur herstellung einer infusionslösung - ofatumumabum 100 mg, natrii acetas trihydricus, dinatrii edetas, polysorbatum 80, argininum, natrii chloridum, aqua ad iniectabilia q.s. zu einer lösung anstelle von 5 ml. - behandlung der chronisch-lymphatischen leukämie - biotechnologika

स्विट्ज़रलैंड - जर्मन - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ofatumumabum - konzentrat zur herstellung einer infusionslösung - ofatumumabum 1000 mg, natrii acetas trihydricus, dinatrii edetas, polysorbatum 80, argininum, natrii chloridum, aqua ad iniectabilia q.s. zu einer lösung statt 50 ml. - behandlung der chronisch-lymphatischen leukämie - biotechnologika

यूरोपीय संघ - जर्मन - EMA (European Medicines Agency)

amgen europe b.v. - carfilzomib - multiples myelom - antineoplastische mittel - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

यूरोपीय संघ - जर्मन - EMA (European Medicines Agency)

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

जर्मनी - जर्मन - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

apontis pharma deutschland gmbh & co. kg (8162914) - schweres magnesiumoxid - hartkapsel - teil 1 - hartkapsel; schweres magnesiumoxid (00186) 250 milligramm

जर्मनी - जर्मन - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

apontis pharma deutschland gmbh & co. kg (8162914) - schweres magnesiumoxid - hartkapsel - teil 1 - hartkapsel; schweres magnesiumoxid (00186) 403 milligramm

स्विट्ज़रलैंड - जर्मन - Swissmedic (Swiss Agency for Therapeutic Products)

gilead sciences switzerland sàrl - idelalisibum - filmtabletten - idelalisibum 100 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carboxymethylamylum natricum, carmellosum natricum conexum, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 110 0.1 mg, pro compresso obducto corresp. natrium 0.732 mg. - onkologikum - synthetika